Evidence map›Paper›PMID 41793220›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026

Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months.

Albert Wolkerstorfer, Melinda J Gooderham, Michael Sebastian, David Rosmarin, Andrew Blauvelt, Maryam Shayesteh Alam, Jacek Zdybski, Shaoceng Wei, Deanna Kornacki, Thierry Passeron and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Albert WolkerstorferAmsterdam University Medical Center, Amsterdam, Netherlands.
Melinda J GooderhamSKiN Centre for Dermatology, Peterborough, Ontario, Canada.ORCID https://orcid.org/0000-0001-8926-0113
Michael SebastianHautarztpraxis Mahlow, Blankenfelde-Mahlow, Germany.
David RosmarinIndiana University School of Medicine, Indianapolis, Indiana, USA.
Andrew BlauveltBlauvelt Consulting, LLC, Annapolis, Maryland, USA.ORCID https://orcid.org/0000-0002-2633-985X
Maryam Shayesteh AlamSimcoDerm Medical and Surgical Dermatology Centre, Barrie, Ontario, Canada.
Jacek ZdybskiKlinika Zdybski - Dermedic, Ostrowiec Swietokrzyski, Poland.
Shaoceng WeiIncyte Corporation, Wilmington, Delaware, USA.
Deanna KornackiIncyte Corporation, Wilmington, Delaware, USA.
Thierry PasseronCentre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
John E HarrisUniversity of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

Funding

Incyte Corporation
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clinical trialJanus kinase inhibitorsruxolitinib creamtherapeutic studiesvitiligo

Identifiers

PMID41793220
PMCPMC13425443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.